Merrill Lynch Downgrades Andrx to 'Neutral'

The biotech firm says it will delay the launch of generic Wellbutrin SR, an antidepressant drug

Merrill Lynch downgraded Andrx (ADRX ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.